BI 764524

DRUG3 trials

Sponsors

Boehringer Ingelheim International GmbH, Boehringer Ingelheim

Conditions

Diabetic RetinopathyDiabetic retinopathy

Phase 1

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

CompletedNCT04424290

Boehringer IngelheimDiabetic Retinopathy

Start: 2020-06-12End: 2023-04-28Updated: 2024-05-22

Phase 2

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Active, not recruitingNCT06321302

Boehringer IngelheimDiabetic Retinopathy

Start: 2024-05-15End: 2027-08-20Updated: 2026-09-16

CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72 week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderate to severe non-proliferative diabetic retinopathy

RecruitingCTIS2023-508891-12-00

Boehringer Ingelheim International GmbHDiabetic retinopathy

Start: 2024-11-28Target: 103Updated: 2026-01-26

Related Papers

HORNBILL: a phase I/IIa trial examining the safety, tolerability and early response of BI 764524 in patients with diabetic retinopathy and diabetic macular ischaemia-rationale, study design and protocol.

2022-08-1710 citations